ArticleJournal of inflammation research2026
Neutrophil-Specific Biomarker S100A2 Mediates Diabetic Foot Ulcer Through IL-17 Signaling Pathway and Potential Therapeutics.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot ulcers (DFU) often lead to infection and amputation, thereby imposing a heavy socioeconomic burden. The limited efficacy of current therapies underscores the urgent need to explore the pathogenesis of DFU. Alterations in the immune response have been reported to influence the pathophysiology of DFU by single-cell RNA sequencing (scRNA-seq) analysis. Therefore, a thorough understanding of the immune microenvironment characteristics of DFU and the intervention of specific immune cell populations could enable the formulation of optimal therapeutic strategies. Methods: Bulk RNA sequencing (bulk RNA-seq) datasets and scRNA-seq datasets were acquired from the Gene Expression Omnibus (GEO) database. The packages "limma", "weighted gene coexpression network analysis (WGCNA)", and "CIBERSORT" were used for bulk RNA-seq analysis to identify the key immune genes. For scRNA-seq, the packages "Seurat" were used for cell clusters identification and annotation. The differential expression of immune hub genes between DFU and diabetic foot skin (DFS) was validated using quantitative real-time polymerase chain reaction (qRT-PCR) and our RNA-seq dataset. A Connectivity Map (CMAP) database was used for computational drug prediction. Results: Using bulk-RNA-seq, seven genes were identified as immune hub genes. Afterwards, six cell populations were recognized by scRNA-seq, with S100A2 predominantly expressed in neutrophils. Moreover, we revealed a robust correlation between the interleukin-17 (IL-17) signaling pathway and S100A2. Secukinumab, ruxolitinib, and leflunomide are potential therapeutic drugs for DFU. Among them, ruxolitinib and leflunomide are clinically available agents, while secukinumab (an IL-17A inhibitor) shows translational potential for repurposing. Conclusion: S100A2 appears to be a promising therapeutic target for the modulation of DFU pathogenesis. Furthermore, neutrophil-mediated inflammatory responses and immune regulation appear to be crucial factors in DFU progression. Notably, this is the first study to identify S100A2 as a neutrophil-specific biomarker linked to IL-17 signaling in DFU, filling the gap of specific gene-immune cell interaction in DFU pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.